Phase 2Active, not recruiting

Safety and Efficacy of Empagliflozin in Hemodialysis (SEED)

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease

Sponsor
NYU Langone Health (Academic or other)
Enrollment
60 planned
Conditions
End Stage Renal Disease
Interventions
Empagliflozin 10 MG; Placebo
Ages
adults, older adults
Registry
NCT05786443

Full record on ClinicalTrials.gov

From the registry

A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.

Primary outcomes

  • Change in Extracellular Volume from Baseline to 12 Weeks
  • Change in Intracellular Volume from Baseline to 12 Weeks
  • Change in Total Body Water from Baseline to 12 Weeks
  • Change in 24-Hour Urine Volume from Baseline to 12 Weeks

History

  1. Primary completion expected

  2. Now active, not recruiting

    , from Recruiting to Active, not recruiting

  3. Last registry update

  4. Started

  5. Registered